CA2485681A1 - Ccr9 inhibitors and methods of use thereof - Google Patents

Ccr9 inhibitors and methods of use thereof Download PDF

Info

Publication number
CA2485681A1
CA2485681A1 CA002485681A CA2485681A CA2485681A1 CA 2485681 A1 CA2485681 A1 CA 2485681A1 CA 002485681 A CA002485681 A CA 002485681A CA 2485681 A CA2485681 A CA 2485681A CA 2485681 A1 CA2485681 A1 CA 2485681A1
Authority
CA
Canada
Prior art keywords
benzenesulfonamide
chloro
benzoyl
phenyl
isopropoxy
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
CA002485681A
Other languages
French (fr)
Other versions
CA2485681C (en
Inventor
Paul Fleming
Geraldine C. B. Harriman
Zhan Shi
Shaowu Chen
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Takeda Pharmaceutical Co Ltd
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Priority to CA2784937A priority Critical patent/CA2784937A1/en
Publication of CA2485681A1 publication Critical patent/CA2485681A1/en
Application granted granted Critical
Publication of CA2485681C publication Critical patent/CA2485681C/en
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C311/00—Amides of sulfonic acids, i.e. compounds having singly-bound oxygen atoms of sulfo groups replaced by nitrogen atoms, not being part of nitro or nitroso groups
    • C07C311/22—Sulfonamides, the carbon skeleton of the acid part being further substituted by singly-bound oxygen atoms
    • C07C311/29—Sulfonamides, the carbon skeleton of the acid part being further substituted by singly-bound oxygen atoms having the sulfur atom of at least one of the sulfonamide groups bound to a carbon atom of a six-membered aromatic ring
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/14—Drugs for genital or sexual disorders; Contraceptives for lactation disorders, e.g. galactorrhoea
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/04—Antipruritics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/14—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C311/00—Amides of sulfonic acids, i.e. compounds having singly-bound oxygen atoms of sulfo groups replaced by nitrogen atoms, not being part of nitro or nitroso groups
    • C07C311/15—Sulfonamides having sulfur atoms of sulfonamide groups bound to carbon atoms of six-membered aromatic rings
    • C07C311/21—Sulfonamides having sulfur atoms of sulfonamide groups bound to carbon atoms of six-membered aromatic rings having the nitrogen atom of at least one of the sulfonamide groups bound to a carbon atom of a six-membered aromatic ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C311/00—Amides of sulfonic acids, i.e. compounds having singly-bound oxygen atoms of sulfo groups replaced by nitrogen atoms, not being part of nitro or nitroso groups
    • C07C311/30—Sulfonamides, the carbon skeleton of the acid part being further substituted by singly-bound nitrogen atoms, not being part of nitro or nitroso groups
    • C07C311/37—Sulfonamides, the carbon skeleton of the acid part being further substituted by singly-bound nitrogen atoms, not being part of nitro or nitroso groups having the sulfur atom of at least one of the sulfonamide groups bound to a carbon atom of a six-membered aromatic ring
    • C07C311/38—Sulfonamides, the carbon skeleton of the acid part being further substituted by singly-bound nitrogen atoms, not being part of nitro or nitroso groups having the sulfur atom of at least one of the sulfonamide groups bound to a carbon atom of a six-membered aromatic ring having sulfur atoms of sulfonamide groups and amino groups bound to carbon atoms of six-membered rings of the same carbon skeleton
    • C07C311/44—Sulfonamides, the carbon skeleton of the acid part being further substituted by singly-bound nitrogen atoms, not being part of nitro or nitroso groups having the sulfur atom of at least one of the sulfonamide groups bound to a carbon atom of a six-membered aromatic ring having sulfur atoms of sulfonamide groups and amino groups bound to carbon atoms of six-membered rings of the same carbon skeleton having the nitrogen atom of at least one of the sulfonamide groups bound to a carbon atom of a six-membered aromatic ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C311/00—Amides of sulfonic acids, i.e. compounds having singly-bound oxygen atoms of sulfo groups replaced by nitrogen atoms, not being part of nitro or nitroso groups
    • C07C311/30—Sulfonamides, the carbon skeleton of the acid part being further substituted by singly-bound nitrogen atoms, not being part of nitro or nitroso groups
    • C07C311/45—Sulfonamides, the carbon skeleton of the acid part being further substituted by singly-bound nitrogen atoms, not being part of nitro or nitroso groups at least one of the singly-bound nitrogen atoms being part of any of the groups, X being a hetero atom, Y being any atom, e.g. N-acylaminosulfonamides
    • C07C311/46—Y being a hydrogen or a carbon atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C317/00—Sulfones; Sulfoxides
    • C07C317/26—Sulfones; Sulfoxides having sulfone or sulfoxide groups and nitrogen atoms, not being part of nitro or nitroso groups, bound to the same carbon skeleton
    • C07C317/32—Sulfones; Sulfoxides having sulfone or sulfoxide groups and nitrogen atoms, not being part of nitro or nitroso groups, bound to the same carbon skeleton with sulfone or sulfoxide groups bound to carbon atoms of six-membered aromatic rings of the carbon skeleton
    • C07C317/34—Sulfones; Sulfoxides having sulfone or sulfoxide groups and nitrogen atoms, not being part of nitro or nitroso groups, bound to the same carbon skeleton with sulfone or sulfoxide groups bound to carbon atoms of six-membered aromatic rings of the carbon skeleton having sulfone or sulfoxide groups and amino groups bound to carbon atoms of six-membered aromatic rings being part of the same non-condensed ring or of a condensed ring system containing that ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C323/00—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups
    • C07C323/23—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and nitrogen atoms, not being part of nitro or nitroso groups, bound to the same carbon skeleton
    • C07C323/46—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and nitrogen atoms, not being part of nitro or nitroso groups, bound to the same carbon skeleton having at least one of the nitrogen atoms, not being part of nitro or nitroso groups, further bound to other hetero atoms
    • C07C323/49—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and nitrogen atoms, not being part of nitro or nitroso groups, bound to the same carbon skeleton having at least one of the nitrogen atoms, not being part of nitro or nitroso groups, further bound to other hetero atoms to sulfur atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/24—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D213/44—Radicals substituted by doubly-bound oxygen, sulfur, or nitrogen atoms, or by two such atoms singly-bound to the same carbon atom
    • C07D213/46—Oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/24—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D213/44—Radicals substituted by doubly-bound oxygen, sulfur, or nitrogen atoms, or by two such atoms singly-bound to the same carbon atom
    • C07D213/46—Oxygen atoms
    • C07D213/50—Ketonic radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/62—Oxygen or sulfur atoms
    • C07D213/63—One oxygen atom
    • C07D213/65—One oxygen atom attached in position 3 or 5
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/62—Oxygen or sulfur atoms
    • C07D213/70—Sulfur atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/62—Oxygen or sulfur atoms
    • C07D213/70—Sulfur atoms
    • C07D213/71—Sulfur atoms to which a second hetero atom is attached
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/72—Nitrogen atoms
    • C07D213/75—Amino or imino radicals, acylated by carboxylic or carbonic acids, or by sulfur or nitrogen analogues thereof, e.g. carbamates
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/72—Nitrogen atoms
    • C07D213/76—Nitrogen atoms to which a second hetero atom is attached
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/78—Carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C07D213/79—Acids; Esters
    • C07D213/80—Acids; Esters in position 3
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/89—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members with hetero atoms directly attached to the ring nitrogen atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D237/00—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings
    • C07D237/02—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings
    • C07D237/06—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members
    • C07D237/08—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/26—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/32—One oxygen, sulfur or nitrogen atom
    • C07D239/42—One nitrogen atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D333/00—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom
    • C07D333/02—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings
    • C07D333/04—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom
    • C07D333/26—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D333/30—Hetero atoms other than halogen
    • C07D333/34—Sulfur atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D333/00—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom
    • C07D333/50—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom condensed with carbocyclic rings or ring systems
    • C07D333/52—Benzo[b]thiophenes; Hydrogenated benzo[b]thiophenes
    • C07D333/62—Benzo[b]thiophenes; Hydrogenated benzo[b]thiophenes with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to carbon atoms of the hetero ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/06—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
    • C07D513/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
    • C07D513/04—Ortho-condensed systems

Abstract

The invention relates to compounds represented by Structural Formula I, whic h can bind to CCR9 receptors and block the binding of a ligand (e.g., TECK) to the receptors. The invention also relates to a method of inhibiting a functi on of CCR9, and to the use compounds represented by Structural Formula I in research, therapeutic, prophylactic and diagnostic methods.

Claims (22)

1. A compound represented by the following structural formula:
or pharmaceutically acceptable salts, solvates or hydrates thereof, wherein:
Y is C(O), O, S, S(O), or S(O)2;
X1, X2, and X3 are each, independently, N or CR, provided that at least one of X1, X2, or X3 is CR;
R for each occurrence and R1 are each, independently, H or a substituent;
R6 is H, an aliphatic carbonyl group, or an aliphatic ester;
ring A is substituted or unsubstituted; and Ar1 and Ar2 are each, independently, a substituted or unsubstituted aryl or a substituted or unsubstituted heteroaryl.
2. The compound of claim 1, wherein Ar2 is phenyl, naphthyl, thienyl, or thianaphthenyl, each group being substituted or unsubstituted.
3. The compound of claim 1, wherein Ar1 is phenyl, pyridyl, pyrimidinyl, or pyrazinyl, each group being substituted or unsubstituted.
4. The compound of claim 1, which is represented by the following structural formula:
or a pharmaceutically acceptable salts, solvates, or hydrates thereof, wherein: Y is S, O, S(O), or S(O)2;
R19 and R20 are each, independently, H or a substituent.
5. The compound of claim 1, which is represented by the following structural formula:
or pharmaceutically acceptable salts, solvates, or hydrates thereof, wherein: R1, R2, R3, R4, R5, and each R are, independently, H, an aliphatic group, haloalkyl, halo, COOH, NO2, alkoxy, or haloalkoxy; and X4 is CR, N or N+ -O-.
6. The compound of claim 1 which is represented by the following structural formula:
or pharmaceutically acceptable salts, solvates, or hydrates thereof, wherein:
X4 is CR, N or N+ -O-;
R8 is H or an electron withdrawing group;
m and n are each, independently, 0 or an integer from 1 to 3;
each R9 is, independently, aliphatic group, haloalkyl, aryl, arylalkyl, alkoxy, cycloalkoxy, haloalkoxy, aryloxy, arylalkoxy, alkylthio, halo, nitro, cyano, hydroxy, NR11CO2R12, C(O)N(R11)2, C(O)R12, CO2R12, OC(O)N(R11)2, OC(O)R12, N(R11)2, or NR11C(O)R12; or two adjacent R9 groups taken together with the atoms to which they are attached form a fused, saturated, unsaturated or partially unsaturated 5 to 7 membered ring having 0, 1 or 2 heteroatoms selected from the group consisting of N, O, and S;
each R10 is, independently, halo, an aliphatic group, alkoxy, or haloalkyl; or two adjacent R10 groups taken together with the atoms to which they are attached form a fused, saturated, unsaturated or partially unsaturated 5 to 7 membered ring having 0, 1 or 2 heteroatoms selected from the group consisting of N, O, and S;
each R11 is, independently, H or an aliphatic group; and R12 is an aliphatic group.
7. The compound of claim 1 wherein the compound is represented by the following structural formula:
or pharmaceutically acceptable salts, solvates, or hydrates thereof, wherein:
ring B is substituted or unsubstituted;
p is 0 or an integer from 1-3; and each R13 is, independently, a halo or a substituted or unsubstituted heteroaryl.
8. A compound selected from the group consisting of:
N-[4-Chloro-2-(2-chloro-benzoyl)-phenyl]-4-nitro-benzenesulfonamide Thiophene-2-sulfonic acid (2-benzoyl-4-chloro-phenyl)-amide N-(2-Benzoyl-4-chloro-phenyl)-4-iodo-benzenesulfonamide N-(2-Benzoyl-4-chloro-phenyl)-4-chloro-benzenesulfonamide N-(2-Benzoyl-4-chloro-phenyl)-4-tert-butyl-benzenesulfonamide N-(2-Benzoyl-4-chloro-phenyl)-4-propyl-benzenesulfonamide N-(2-Benzoyl-4-chloro-phenyl)-4-ethyl-benzenesulfonamide N-(2-Benzoyl-4-nitro-phenyl)-4-ethyl-benzenesulfonamide N-(2-Benzoyl-4-chloro-phenyl)-4-isopropyl-benzenesulfonamide N-(2-Benzoyl-4-bromo-phenyl)-4-ethyl-benzenesulfonamide N-(2-Benzoyl-4-bromo-phenyl)-4-methoxy-benzenesulfonamide N-(2-Benzoyl-4-bromo-phenyl)-4-isopropyl-benzenesulfonamide 4-Ethyl-N-[4-nitro-2-(3-trifluoromethyl-benzoyl)-phenyl]-benzenesulfonamide N-[4-Chloro-2-(3-methyl-benzoyl)-phenyl]-4-ethyl-benzenesulfonamide N-(2-Benzoyl-4-bromo-phenyl)-4-chloro-benzenesulfonamide N-(2-Benzoyl-4-chloro-phenyl)-4-ethoxy-benzenesulfonamide N-(2-Benzoyl-4-chloro-phenyl)-4-propoxy-benzenesulfonamide N-(2-Benzoyl-4-chloro-phenyl)-4-isopropoxy-benzenesulfonamide N-(2-Benzoyl-4-chloro-phenyl)-4-butoxy-benzenesulfonamide N-(2-Benzoyl-4-chloro-phenyl)-4-benzyloxy-benzenesulfonamide N-(2-Benzoyl-4-chloro-phenyl)-4-phenoxy-benzenesulfonamide N-(3-Benzoyl-5-chloro-pyridin-2-yl)-4-isopropoxy-benzenesulfonamide N-[4-Chloro-2-(pyridine-4-carbonyl)-phenyl]-4-ethoxy-benzenesulfonamide N-[4-Chloro-2-(pyridine-4-carbonyl)-phenyl]-4-isopropyl-benzenesulfonamide N-[4-Chloro-2-(pyridine-4-carbonyl)-phenyl]-4-isobutyl-benzenesulfonamide N-[5-Chloro-3-(pyridine-4-carbonyl)-pyridin-2-yl]-4-ethoxy-benzenesulfonamide N-[5-Chloro-3-(pyridine-4-carbonyl)-pyridin-2-yl]-4-isopropoxy-benzenesulfonamide N-(3-Benzoyl-5-trifluoromethyl-pyridin-2-yl)-4-isopropoxy-benzenesulfonamide N-(2-Benzoyl-4-nitro-phenyl)-4-chloro-benzenesulfonamide 5-Benzoyl-6-(4-isopropoxy-benzenesulfonylamino)-nicotinic acid N-(2-Benzoyl-4-chloro-phenyl)-2-nitro-benzenesulfonamide N-(3-Benzoyl-5-nitro-pyridin-2-yl)-4-isopropoxy-benzenesulfonamide N-(5-Benzoyl-pyrimidin-4-yl)-4-isopropoxy-benzenesulfonamide N-(3-Benzoyl-5-trifluoromethoxy-pyridin-2-yl)-4-isopropoxy-benzenesulfonamide N-(5-Benzoyl-2-trifluoromethyl-pyrimidin-4-yl)-4-isopropoxy-benzenesulfonamide N-(3-Benzoyl-5-chloro-pyridin-2-yl)-4-cyclopropoxy-benzenesulfonamide N-(3-Benzoyl-5-chloro-pyridin-2-yl)-4-cyclobutyl-benzenesulfonamide N-(3-Benzoyl-5-chloro-pyridin-2-yl)-4-tert-butoxy-benzenesulfonamide N-(3-Benzoyl-5-chloro-pyridin-2-yl)-4-cyclopentyl-benzenesulfonamide N-(3-Benzoyl-5-chloro-pyridin-2-yl)-4-isopropylsulfanyl-benzenesulfonamide N-(3-Benzoyl-5-chloro-pyridin-2-yl)-4-isopropylamino-benzenesulfonamide N-(3-Benzoyl-5-chloro-pyridin-2-yl)-4-cyclopropyl-benzenesulfonamide N-(3-Benzoyl-5-chloro-pyridin-2-yl)-4-cyclohexyl-benzenesulfonamide N-(3-Benzenesulfinyl-5-chloro-pyridin-2-yl)-4-isopropoxy-benzenesulfonamide N-(3-Benzenesulfonyl-5-chloro-pyridin-2-yl)-4-isopropoxy-benzenesulfonamide N-[4-Chloro-2-(pyrimidine-5-carbonyl)-phenyl]-4-isopropoxy-benzenesulfonamide N-[4-Chloro-2-(pyridazine-4-carbonyl)-phenyl]-4-isopropoxy-benzenesulfonamide N-[4-Chloro-2-(2-trifluoromethyl-pyrimidine-5-carbonyl)-phenyl]-4-isopropoxy-benzenesulfonamide N-[4-Chloro-2-(6-trifluoromethyl-pyridazine-4-carbonyl)-phenyl]-4-isopropoxy-benzenesulfonamide N-[4-Chloro-2-(2-trifluoromethyl-pyrimidine-5-carbonyl)-phenyl]-4-isopropoxy-benzenesulfonamide N-[4-Chloro-2-(6-trifluoromethyl-pyridazine-4-carbonyl)-phenyl]-4-isopropoxy-benzenesulfonamide N-(2-Benzoyl-4-nitro-phenyl)-4-isopropyl-benzenesulfonamide N-(2-Benzoyl-4-nitro-phenyl)-4-isopropoxy-benzenesulfonamide N-(2-Benzoyl-4-nitro-phenyl)-4-methoxy-benzenesulfonamide N-(2-Benzoyl-4-chloro-phenyl)-4-trifluoromethoxy-benzenesulfonamide 5-Oxazol-5-yl-thiophene-2-sulfonic acid (2-benzoyl-4-chloro-phenyl)-amide N-[4-Chloro-2-(3-chloro-benzoyl)-phenyl]-4-methoxy-benzenesulfonamide N-(2-Benzoyl-4-chloro-phenyl)-4-methoxy-benzenesulfonamide N-[4-Chloro-2-(3-chloro-benzoyl)-phenyl]-4-ethyl-benzenesulfonamide N-(2-Benzoyl-4-chloro-phenyl)-4-ethylamino-benzenesulfonamide 5-(1-Methyl-5-trifluoromethyl-1H-pyrazol-3-yl)-thiophene-2-sulfonic acid (2-benzoyl-4-chloro-phenyl)-amide N-(2-Benzoyl-4-iodo-phenyl)-4-isopropoxy-benzenesulfonamide N-[4-Chloro-2-(3-fluoro-benzoyl)-phenyl]-4-methyl-benzenesulfonamide N-[4-Chloro-2-(3-chloro-benzoyl)-phenyl]-4-isopropyl-benzenesulfonamide N-(2-Benzoyl-4-chloro-phenyl)-4-nitro-benzenesulfonamide N-(2-Benzoyl-4-chloro-phenyl)-4-diethylamino-benzenesulfonamide N-(2-Benzoyl-4-fluoro-phenyl)-4-methoxy-benzenesulfonamide 4-Chloro-N-[4-chloro-2-(pyridine-3-carbonyl)-phenyl]-benzenesulfonamide N-(2-Benzoyl-4-bromo-phenyl)-4-methyl-benzenesulfonamide N-(2-Benzoyl-4-chloro-phenyl)-4-bromo-benzenesulfonamide N-[4-Chloro-2-(pyridine-3-carbonyl)-phenyl]-4-methoxy-benzenesulfonamide N-(2-Benzoyl-4-chloro-phenyl)-4-dimethylamino-benzenesulfonamide N-(2-Benzoyl-4-chloro-phenyl)-4-fluoro-benzenesulfonamide 4-Chloro-N-[4-chloro-2-(2-fluoro-benzoyl)-phenyl]-benzenesulfonamide N-[4-Chloro-2-(2-fluoro-benzoyl)-phenyl]-4-methoxy-benzenesulfonamide Thiophene-3-sulfonic acid (2-benzoyl-4-chloro-phenyl)-amide 5-Bromo-thiophene-2-sulfonic acid (2-benzoyl-4-chloro-phenyl)-amide 5-Chloro-thiophene-2-sulfonic acid (2-benzoyl-4-chloro-phenyl)-amide N-[4-Chloro-2-(2-fluoro-benzoyl)-phenyl]-4-nitro-benzenesulfonamide N-[4-Chloro-2-(2-fluoro-benzoyl)-phenyl]-4-methyl-benzenesulfonamide 4-Chloro-N-[4-chloro-2-(pyridine-2-carbonyl)-phenyl]-benzenesulfonamide N-(2-Benzoyl-4-chloro-phenyl)-benzenesulfonamide N-[4-(2-Benzoyl-4-chloro-phenylsulfamoyl)-phenyl]-acetamide N-[4-Chloro-2-(pyridine-2-carbonyl)-phenyl]-4-methoxy-benzenesulfonamide N-[4-Chloro-2-(pyridine-2-carbonyl)-phenyl]-4-methyl-benzenesulfonamide N-(2-Benzoyl-4-chloro-phenyl)-4-cyano-benzenesulfonamide 4,5-Dibromo-thiophene-2-sulfonic acid (2-benzoyl-4-chloro-phenyl)-amide N-[4-Chloro-2-(pyridine-3-sulfonyl)-phenyl]-4-nitro-benzenesulfonamide Naphthalene-2-sulfonic acid [4-chloro-2-(pyridine-3-carbonyl)-phenyl]-amide N-(2-Benzoyl-4-chloro-phenyl)-3-bromo-benzenesulfonamide N-(2-Benzoyl-4-chloro-phenyl)-4-methyl-3-nitro-benzenesulfonamide N-[4-Chloro-2-(2-methoxy-benzoyl)-phenyl]-4-nitro-benzenesulfonamide N-(2-Benzoyl-4-chloro-phenyl)-2-trifluoromethyl-benzenesulfonamide 5-Chloro-3-methyl-benzo[b]thiophene-2-sulfonic acid (2-benzoyl-4-chloro-phenyl)-amide N-(2-Benzoyl-phenyl)-4-nitro-benzenesulfonamide 5-Isoxazol-3-yl-thiophene-2-sulfonic acid (2-benzoyl-4-chloro-phenyl)-amide N-(2-Benzoyl-phenyl)-4-methyl-benzenesulfonamide Benzo[b]thiophene-3-sulfonic acid (2-benzoyl-4-chloro-phenyl)-amide N-(4-Chloro-2-phenylsulfanyl-phenyl)-4-isopropoxy-benzenesulfonamide N-(2-Benzenesulfonyl-4-chloro-phenyl)-4-isopropoxy-benzenesulfonamide N-[4-Chloro-2-(pyridine-4-carbonyl)-phenyl]-4-isopropoxy-benzenesulfonamide N-[4-Chloro-2-(1-oxy-pyridine-4-carbonyl)-phenyl]-4-isopropoxy-benzenesulfonamide 4-Isopropoxy-N-[2-(pyridine-4-carbonyl)-4-trifluoromethyl-phenyl]-benzenesulfonamide 4-Ethoxy-N-[2-(pyridine-4-carbonyl)-4-trifluoromethyl-phenyl]-benzenesulfonamide N-[5-Chloro-3-(3-fluoro-benzoyl)-pyridin-2-yl]-4-isopropyl-benzenesulfonamide N-[5-Chloro-3-(3-fluoro-benzoyl)-pyridin-2-yl]-4-isopropoxy-benzenesulfonamide N-[5-Chloro-3-(thiophene-2-carbonyl)-pyridin-2-yl]-4-isopropoxy-benzenesulfonamide 5-Oxazol-5-yl-thiophene-2-sulfonic acid [5-chloro-3-(3-fluoro-benzoyl)-pyridin-2-yl]-amide N-[3-(Benzofuran-2-carbonyl)-5-chloro-pyridin-2-yl]-4-isopropoxy-benzenesulfonamide N-(2-Benzoyl-4-trifluoromethyl-phenyl)-4-isopropoxy-benzenesulfonamide N-(3-Benzoyl-pyridin-4-yl)-4-isopropoxy-benzenes N-(3-Benzoyl-5-chloro-pyridin-2-yl)-4-isopropyl-benzenesulfonamide N-(3-Benzoyl-5-nitro-pyridin-2-yl)-4-isopropoxy-benzenesulfonamide 5-Oxazol-5-yl-thiophene-2-sulfonic acid (3-benzoyl-5-chloro-pyridin-2-yl)-amide N-(2-Benzoyl-4-chloro-phenyl)-4-isopropylamino-benzenesulfonamide N-(4-Benzoyl-pyridin-3-yl)-4-isopropyl-benzenesulfonamide N-(4-Benzoyl-pyridin-3-yl)-4-isopropoxy-benzenesulfonamide N-[4-Chloro-2-(pyridin-3-yloxy)-phenyl]-4-isopropyl-benzenesulfonamide N-(2.-Benzoyl-pyridin-3-yl)-4-isopropoxy-benzenesulfonamide N-[3-(3-Fluoro-benzoyl)-pyridin-2-yl]-4-isopropoxy-benzenesulfonamide N-[4-Chloro-2-(pyridin-3-yloxy)-phenyl]-4-isopropoxy-benzenesulfonamide 4-Isopropoxy-N-[3-(pyridine-4-carbonyl)-pyridin-4-yl]-benzenesulfonamide 6-Isopropoxy-pyridine-3-sulfonic acid (3-benzoyl-5-chloro-pyridin-2-yl)-amide 6-Isopropoxy-pyridine-3-sulfonic acid (2-benzoyl-4-chloro-phenyl)-amide N-[4-Chloro-2-(pyridin-2-ylsulfanyl)-phenyl]-4-isopropyl-benzenesulfonamide N-(2-Benzoyl-phenyl)-4-isopropoxy-benzenesulfonamide; and pharmaceutically acceptable salts, solvates, and hydrates thereof.
9. A pharmaceutical composition, comprising a pharmaceutically acceptable carrier and the compound of claim 1.
10. A method of inhibiting a CCR9 receptor function in a subject in need thereof, comprising the step of administering to the subject an effective amount of a compound represented by the following structural formula:
or pharmaceutically acceptable salts, solvates or hydrates thereof, wherein:
Y is C(O), S, O, S(O) or S(O)2;
X1, X2, and X3 are each, independently, N or CR, provided that at least one of X1, X2, or X3 is CR;
R, for each occurrence, and R1 are each, independently, H or a substituent;
R6 is H, an aliphatic carbonyl group, or an aliphatic ester; and ring A is substituted or unsubstituted;
Ar1 and Ar2 are each, independently, a substituted or unsubstituted aryl group or a substituted or unsubstituted heteroaryl group.
11. The method of claim 10, wherein the compound is represented by a structural formula selected from the group consisting of A, B, C, and D:

A.

or pharmaceutically acceptable salts, solvates or hydrates thereof, wherein: R19 and R20 are each, independently, H or a substituent;

B.
or pharmaceutically acceptable salts, solvates or hydrates thereof, wherein: Rl, R2, R3, R4, R5, and each R are, independently, H, an aliphatic group, haloalkyl, a halo, COOH, NO2, alkoxy, or haloalkoxy; and X4 is CR, N or N+-O-;

C.
or pharmaceutically acceptable salts, solvates or hydrates thereof, wherein:

X4 is CR, N or N+-O-;
R8 is H or an electron withdrawing group;
m and n are each, independently, 0 or an integer from 1 to 3;
each R9 is, independently, an aliphatic group, haloalkyl, aryl, arylalkyl, alkoxy, cycloalkoxy, haloalkoxy, aryloxy, arylalkoxy, alkylthio, halo, nitro, cyano, hydroxy, NR11CO2R12, C(O)N(R11)2, C(O)R12, CO2R12, OC(O)N(R11)2, OC(O)R12, N(R11)2, or NR11C(O)R12; or two adjacent R9 groups taken together with the atoms to which they are attached form a fused, saturated, unsaturated or partially unsaturated 5 to 7 membered ring having 0, 1 or 2 heteroatoms selected from the group consisting of N, O, and S;

each R10 is, independently, halo, aliphatic group, alkoxy, or haloalkyl; or two adjacent R10 groups taken together with the atoms to which they are attached form a fused, saturated, unsaturated or partially unsaturated 5 to 7 membered ring having 0, 1 or 2 heteroatoms selected from the group consisting of N, O, and S;
each R11 is, independently, H or an aliphatic group; and R12 is an aliphatic group; and D.

or pharmaceutically acceptable salts, solvates or hydrates thereof, wherein:
R8 is halo, nitro, alkylcarbonyl or trihaloalkyl;
p is 0 or an integer from 1 to 3; and each R13 is, independently, a halo, a substituted or unsubstituted heterocycle, or a substituted or unsubstituted heteroaryl.
12. The method of claim 10 wherein the subject is being treated for an inflammatory disease or condition.
13. A method of treating or preventing an inflammatory disease or condition in a subject in need thereof, comprising administering to the subject an effective amount of a compound represented by the following structural formula:
or pharmaceutically acceptable salts, solvates or hydrates thereof, wherein:
Y is C(O), S, O, S(O) or S(O)2;
X1, X2, and X3 are each, independently, N or CR, provided that at least one of X1, X2, or X3 is CR;
R, for each occurrence, and R1 are each, independently, H or a substituent;
and ring A is substituted or unsubstituted;
R6 is H, an aliphatic group, an aryl group or an aliphatic carbonyl group; and Ar1 and Ar2 are each, independently, a substituted or unsubstituted aryl group or a substituted or unsubstituted heteroaryl group.
14. The method of claim 13, wherein the compound is represented by a structural formula selected from the group consisting of A,B, C, and D:

A.

or pharmaceutically acceptable salts, solvates or hydrates thereof, wherein: R19 and R20 are each, independently, H or a substituent.

B

or pharmaceutically acceptable salts, solvates or hydrates thereof, wherein: R1, R2, R3, R4, R5, and each R are, independently, H, an aliphatic group, haloalkyl, halo, COOH, NO2, alkoxy, or haloalkoxy; and X4 is CR, N or N+-O-;

C
or pharmaceutically acceptable salts, solvates or hydrates thereof, wherein:
X4 is CR, N or N+-O-;
R8 is H or an electron withdrawing group;
m and n are each, independently, 0 or an integer from 1 to 3;
each R9 is, independently, aliphatic group, haloalkyl, aryl, arylalkyl, alkoxy, cycloalkoxy, haloalkoxy, aryloxy, arylalkoxy, alkylthio, halo, nitro, cyano, hydroxy, NR11CO2R12, C(O)N(R11)2, C(O)R12, CO2R12, OC(O)N(R11)2, OC(O)R12, N(R11)2, or NR11C(O)R12, or two adjacent R9 groups taken together with the atoms to which they are attached form a fused, saturated, unsaturated or partially unsaturated 5 to 7 membered ring having 0, 1 or 2 heteroatoms selected from the group consisting of N, O, and S;
each R10 is, independently, halo, aliphatic group, alkoxy, or haloalkyl; or two adjacent R10 groups taken together with the atoms to which they are attached form a fused, saturated, unsaturated or partially unsaturated 5 to 7 membered ring having 0, 1 or 2 heteroatoms selected from the group consisting of N, O, and S;
each R11 is, independently, H or an aliphatic group; and R12 is an aliphatic group; and D.
or pharmaceutically acceptable salts, solvates or hydrates thereof, wherein:
R8 is a halo, nitro, alkylcarbonyl or trihaloalkyl;
p is 0 or an integer from 1 to 3; and each R13 is, independently, a halo, a substituted or unsubstituted heterocycle, or a substituted or unsubstituted heteroaryl.
15. The method of claim 13, wherein the compound is selected from the group consisting of:

N-[4-Chloro-2-(2-chloro-benzoyl)-phenyl]-4-nitro-benzenesulfonamide Thiophene-2-sulfonic acid (2-benzoyl-4-chloro-phenyl)-amide N-(2-Benzoyl-4-chloro-phenyl)-4-iodo-benzenesulfonamide N-(2-Benzoyl-4-chloro-phenyl)-4-chloro-benzenesulfonamide N-(2-Benzoyl-4-chloro-phenyl)-4-tert-butyl-benzenesulfonamide N-(2-Benzoyl-4-chloro-phenyl)-4-propyl-benzenesulfonamide N-(2-Benzoyl-4-chloro-phenyl)-4-ethyl-benzenesulfonamide N-(2-Benzoyl-4-nitro-phenyl)-4-ethyl-benzenesulfonamide N-(2-Benzoyl-4-chloro-phenyl)-4-isopropyl-benzenesulfonamide N-(2-Benzoyl-4-bromo-phenyl)-4-ethyl-benzenesulfonamide N-(2-Benzoyl-4-bromo-phenyl)-4-methoxy-benzenesulfonamide N-(2-Benzoyl-4-bromo-phenyl)-4-isopropyl-benzenesulfonamide 4-Ethyl-N-[4-nitro-2-(3-trifluoromethyl-benzoyl)-phenyl]-benzenesulfonamide N-[4-Chloro-2-(3-methyl-benzoyl)-phenyl]-4-ethyl-benzenesulfonamide N-(2-Benzoyl-4-bromo-phenyl)-4-chloro-benzenesulfonamide N-(2-Benzoyl-4-chloro-phenyl)-4-ethoxy-benzenesulfonamide N-(2-Benzoyl-4-chloro-phenyl)-4-propoxy-benzenesulfonamide N-(2-Benzoyl-4-chloro-phenyl)-4-isopropoxy-benzenesulfonamide N-(2-Benzoyl-4-chloro-phenyl)-4-butoxy-benzenesulfonamide N-(2-Benzoyl-4-chloro-phenyl)-4-benzyloxy-benzenesulfonamide N-(2-Benzoyl-4-chloro-phenyl)-4-phenoxy-benzenesulfonamide N-(3-Benzoyl-5-chloro-pyridin-2-yl)-4-isopropoxy-benzenesulfonamide N-[4-Chloro-2-(pyridine-4-carbonyl)-phenyl]-4-ethoxy-benzenesulfonamide N-[4-Chloro-2-(pyridine-4-carbonyl)-phenyl]-4-isopropyl-benzenesulfonamide N-[4-Chloro-2-(pyridine-4-carbonyl)-phenyl]-4-isobutyl-benzenesulfonamide N-[5-Chloro-3-(pyridine-4-carbonyl)-pyridin-2-yl]-4-ethoxy-benzenesulfonamide N-[5-Chloro-3-(pyridine-4-carbonyl)-pyridin-2-yl]-4-isopropoxy-benzenesulfonamide N-(3-Benzoyl-5-trifluoromethyl-pyridin-2-yl)-4-isopropoxy-benzenesulfonamide N-(2-Benzoyl-4-nitro-phenyl)-4-chloro-benzenesulfonamide 5-Benzoyl-6-(4-isopropoxy-benzenesulfonylamino)-nicotinic acid N-(2-Benzoyl-4-chloro-phenyl)-2-nitro-benzenesulfonamide N-(3-Benzoyl-5-nitro-pyridin-2-yl)-4-isopropoxy-benzenesulfonamide N-(5-Benzoyl-pyrimidin-4-yl)-4-isopropoxy-benzenesulfonamide N-(3-Benzoyl-5-trifluoromethoxy-pyridin-2-yl)-4-isopropoxy-benzenesulfonamide N-(5-Benzoyl-2-trifluoromethyl-pyrimidin-4-yl)-4-isopropoxy-benzenesulfonamide N-(3-Benzoyl-5-chloro-pyridin-2-yl)-4-cyclopropoxy-benzenesulfonamide N-(3-Benzoyl-5-chloro-pyridin-2-yl)-4-cyclobutyl-benzenesulfonamide N-(3-Benzoyl-5-chloro-pyridin-2-yl)-4-tert-butoxy-benzenesulfonamide N-(3-Benzoyl-5-chloro-pyridin-2-yl)-4-cyclopentyl-benzenesulfonamide N-(3-Benzoyl-5-chloro-pyridin-2-yl)-4-isopropylsulfanyl-benzenesulfonamide N-(3-Benzoyl-5-chloro-pyridin-2-yl)-4-isopropylamino-benzenesulfonamide N-(3-Benzoyl-5-chloro-pyridin-2-yl)-4-cyclopropyl-benzenesulfonamide N-(3-Benzoyl-5-chloro-pyridin-2-yl)-4-cyclohexyl-benzenesulfonamide N-(3-Benzenesulfinyl-5-chloro-pyridin-2-yl)-4-isopropoxy-benzenesulfonamide N-(3-Benzenesulfonyl-5-chloro-pyridin-2-yl)-4-isopropoxy-benzenesulfonamide N-[4-Chloro-2-(pyrimidine-5-carbonyl)-phenyl]-4-isopropoxy-benzenesulfonamide N-[4-Chloro-2-(pyridazine-4-carbonyl)-phenyl]-4-isopropoxy-benzenesulfonamide N-[4-Chloro-2-(2-trifluoromethyl-pyrimidine-5-carbonyl)-phenyl]-4-isopropoxy-benzenesulfonamide N-[4-Chloro-2-(6-trifluoromethyl-pyridazine-4-carbonyl)-phenyl]-4-isopropoxy-benzenesulfonamide N-[4-Chloro-2-(2-trifluoromethyl-pyrimidine-5-carbonyl)-phenyl]-4-isopropoxy-benzenesulfonamide N-[4-Chloro-2-(6-trifluoromethyl-pyridazine-4-carbonyl)-phenyl]-4-isopropoxy-benzenesulfonamide N-(2-Benzoyl-4-nitro-phenyl)-4-isopropyl-benzenesulfonamide N-(2-Benzoyl-4-nitro-phenyl)-4-isopropoxy-benzenesulfonamide N-(2-Benzoyl-4-nitro-phenyl)-4-methoxy-benzenesulfonamide N-(2-Benzoyl-4-chloro-phenyl)-4-trifluoromethoxy-benzenesulfonamide 5-Oxazol-5-yl-thiophene-2-sulfonic acid (2-benzoyl-4-chloro-phenyl)-amide N-[4-Chloro-2-(3-chloro-benzoyl)-phenyl]-4-methoxy-benzenesulfonamide N-(2-Benzoyl-4-chloro-phenyl)-4-methoxy-benzenesulfonamide N-[4-Chloro-2-(3-chloro-benzoyl)-phenyl]-4-ethyl-benzenesulfonamide N-(2-Benzoyl-4-chloro-phenyl)-4-ethylamino-benzenesulfonamide 5-(1-Methyl-5-trifluoromethyl-1H-pyrazol-3-yl)-thiophene-2-sulfonic acid (2-benzoyl-4-chloro-phenyl)-amide N-(2-Benzoyl-4-iodo-phenyl)-4-isopropoxy-benzenesulfonamide N-[4-Chloro-2-(3-fluoro-benzoyl)-phenyl]-4-methyl-benzenesulfonamide N-[4-Chloro-2-(3-chloro-benzoyl)-phenyl]-4-isopropyl-benzenesulfonamide N-(2-Benzoyl-4-chloro-phenyl)-4-nitro-benzenesulfonamide N-(2-Benzoyl-4-chloro-phenyl)-4-diethylamino-benzenesulfonamide N-(2-Benzoyl-4-fluoro-phenyl)-4-methoxy-benzenesulfonamide 4-Chloro-N-[4-chloro-2-(pyridine-3-carbonyl)-phenyl]-benzenesulfonamide N-(2-Benzoyl-4-bromo-phenyl)-4-methyl-benzenesulfonamide N-(2-Benzoyl-4-chloro-phenyl)-4-bromo-benzenesulfonamide N-[4-Chloro-2-(pyridine-3-carbonyl)-phenyl]-4-methoxy-benzenesulfonamide N-(2-Benzoyl-4-chloro-phenyl)-4-dimethylamino-benzenesulfonamide N-(2-Benzoyl-4-chloro-phenyl)-4-fluoro-benzenesulfonamide 4-Chloro-N-[4-chloro-2-(2-fluoro-benzoyl)-phenyl]-benzenesulfonamide N-[4-Chloro-2-(2-fluoro-benzoyl)-phenyl]-4-methoxy-benzenesulfonamide Thiophene-3-sulfonic acid (2-benzoyl-4-chloro-phenyl)-amide 5-Bromo-thiophene-2-sulfonic acid (2-benzoyl-4-chloro-phenyl)-amide 5-Chloro-thiophene-2-sulfonic acid (2-benzoyl-4-chloro-phenyl)-amide N-[4-Chloro-2-(2-fluoro-benzoyl)-phenyl]-4-nitro-benzenesulfonamide N-[4-Chloro-2-(2-fluoro-benzoyl)-phenyl]-4-methyl-benzenesulfonamide 4-Chloro-N-[4-chloro-2-(pyridine-2-carbonyl)-phenyl]-benzenesulfonamide N-(2-Benzoyl-4-chloro-phenyl)-benzenesulfonamide N-[4-(2-Benzoyl-4-chloro-phenylsulfamoyl)-phenyl]-acetamide N-[4-Chloro-2-(pyridine-2-carbonyl)-phenyl]-4-methoxy-benzenesulfonamide N-[4-Chloro-2-(pyridine-2-carbonyl)-phenyl]-4-methyl-benzenesulfonamide N-(2-Benzoyl-4-chloro-phenyl)-4-cyano-benzenesulfonamide 4,5-Dibromo-thiophene-2-sulfonic acid (2-benzoyl-4-chloro-phenyl)-amide N-[4-Chloro-2-(pyridine-3-sulfonyl)-phenyl]-4-nitro-benzenesulfonamide Naphthalene-2-sulfonic acid [4-chloro-2-(pyridine-3-carbonyl)-phenyl]-amide N-(2-Benzoyl-4-chloro-phenyl)-3-bromo-benzenesulfonamide N-(2-Benzoyl-4-chloro-phenyl)-4-methyl-3-nitro-benzenesulfonamide N-[4-Chloro-2-(2-methoxy-benzoyl)-phenyl]-4-nitro-benzenesulfonamide N-(2-Benzoyl-4-chloro-phenyl)-2-trifluoromethyl-benzenesulfonamide 5-Chloro-3-methyl-benzo[b]thiophene-2-sulfonic acid (2-benzoyl-4-chloro-phenyl)-amide N-(2-Benzoyl-phenyl)-4-nitro-benzenesulfonamide 5-Isoxazol-3-yl-thiophene-2-sulfonic acid (2-benzoyl-4-chloro-phenyl)-amide N-(2-Benzoyl-phenyl)-4-methyl-benzenesulfonamide Benzo[b]thiophene-3-sulfonic acid (2-benzoyl-4-chloro-phenyl)-amide N-(4-Chloro-2-phenylsulfanyl-phenyl)-4-isopropoxy-benzenesulfonamide N-(2-Benzenesulfonyl-4-chloro-phenyl)-4-isopropoxy-benzenesulfonamide N-[4-Chloro-2-(pyridine-4-carbonyl)-phenyl]-4-isopropoxy-benzenesulfonamide N-[4-Chloro-2-(1-oxy-pyridine-4-carbonyl)-phenyl]-4-isopropoxy-benzenesulfonamide 4-Isopropoxy-N-[2-(pyridine-4-carbonyl)-4-trifluoromethyl-phenyl]-benzenesulfonamide 4-Ethoxy-N-[2-(pyridine-4-carbonyl)-4-trifluoromethyl-phenyl]-benzenesulfonamide N-[5-Chloro-3-(3-fluoro-benzoyl)-pyridin-2-yl]-4-isopropyl-benzenesulfonamide N-[5-Chloro-3-(3-fluoro-benzoyl)-pyridin-2-yl]-4-isopropoxy-benzenesulfonamide N-[5-Chloro-3-(thiophene-2-carbonyl)-pyridin-2-yl]-4-isopropoxy-benzenesulfonamide 5-Oxazol-5-yl-thiophene-2-sulfonic acid [5-chloro-3-(3-fluoro-benzoyl)-pyridin-2-yl]-amide N-[3-(Benzofuran-2-carbonyl)-5-chloro-pyridin-2-yl]-4-isopropoxy-benzenesulfonamide N-(2-Benzoyl-4-trifluoromethyl-phenyl)-4-isopropoxy-benzenesulfonamide N-(3-Benzoyl-pyridin-4-yl)-4-isopropoxy-benzenesulfonamide N-(3-Benzoyl-5-chloro-pyridin-2-yl)-4-isopropyl-benzenesulfonamide N-(3-Benzoyl-5-nitro-pyridin-2-yl)-4-isopropoxy-benzenesulfonamide 5-Oxazol-5-yl-thiophene-2-sulfonic acid (3-benzoyl-5-chloro-pyridin-2-yl)-amide N-(2-Benzoyl-4-chloro-phenyl)-4-isopropylamino-benzenesulfonamide N-(4-Benzoyl-pyridin-3-yl)-4-isopropyl-benzenesulfonamide N-(4-Benzoyl-pyridin-3-yl)-4-isopropoxy-benzenesulfonamide N-[4-Chloro-2-(pyridin-3-yloxy)-phenyl]-4-isopropyl-benzenesulfonamide N-(2-Benzoyl-pyridin-3-yl)-4-isopropoxy-benzenesulfonamide N-[3-(3-Fluoro-benzoyl)-pyridin-2-yl]-4-isopropoxy-benzenesulfonamide N-[4-Chloro-2-(pyridin-3-yloxy)-phenyl]-4-isopropoxy-benzenesulfonamide 4-Isopropoxy-N-[3-(pyridine-4-carbonyl)-pyridin-4-yl]-benzenesulfonamide 6-Isopropoxy-pyridine-3-sulfonic acid (3-benzoyl-5-chloro-pyridin-2-yl)-amide 6-Isopropoxy-pyridine-3-sulfonic acid (2-benzoyl-4-chloro-phenyl)-amide N-[4-Chloro-2-(pyridin-2-ylsulfanyl)-phenyl]-4-isopropyl-benzenesulfonamide N-(2-Benzoyl-phenyl)-4-isopropoxy-benzenesulfonamide; and pharmaceutically acceptable salts, solvates, and hydrates thereof.
16. The method of claim 13, wherein the inflammatory disease or condition is Crohn's disease or colitis.
17. The method of claim 13, wherein the inflammatory disease or condition is Celiac's disease.
18. The method of claim 13, wherein the compound inhibits the binding of a ligand to CCR9.
19. The method of claim 18, wherein the ligand is TECK.
20. A method of inhibiting CCR9-mediated homing of leukocytes in a subject in need of such treatment comprising administering to the subject an effective amount of at least one compound represented by the following structural formula:
or pharmaceutically acceptable salts, solvates or hydrates thereof, wherein:
Y is C(O), S, S(O) or S(O)2;
X1, X2, and X3 are each, independently, N or CR, provided that at least one of X1, X2, or X3 is CR;
R, for each occurrence, and R1 are each, independently, H or a substituent;
R6 is H, an aliphatic group, an aryl group or an aliphatic carbonyl group;
ring A is substituted or unsubstituted; and Ar1 and Ar2 are each, independently, a substituted or unsubstituted aryl group or a substituted or unsubstituted heteroaryl group.
21. The method of claim 20, wherein the compound is represented by a structural formula selected from the group consisting of A, B, C, and D:

A.

or pharmaceutically acceptable salts, solvates or hydrates thereof, wherein: R19 and R20 are each, independently, H or a substituent.

B.

or pharmaceutically acceptable salts, solvates or hydrates thereof, wherein: R1, R2, R3, R4, R5, and each R are, independently, H, an aliphatic group, haloalkyl, halo, COOH, NO2, alkoxy, or haloalkoxy; and X4 is CR, N or N+-O-;

C.

or pharmaceutically acceptable salts, solvates or hydrates thereof, wherein:
X4 is CR, N or N+-O-;
R8 is H or an electron withdrawing group;
m and n are each, independently, 0 or an integer from 1 to 3;
each R9 is, independently, an aliphatic group, haloalkyl, aryl, arylalkyl, alkoxy, cycloalkoxy, haloalkoxy, aryloxy, arylalkoxy, alkylthio, halo, nitro, cyano, hydroxy, NR11CO2,R12, C(O)N(R11)2, C(O)R12, CO2R12, OC(O)N(R11)2, OC(O)R12, N(R11)2, or NR11C(O)R12; or two adjacent R9 groups taken together with the atoms to which they are attached form a fused, saturated, unsaturated or partially unsaturated 5 to 7 membered ring having 0, 1 or 2 heteroatoms selected from the group consisting of N, O, and S;

each R10 is, independently, halo, aliphatic group, alkoxy, or haloalkyl; or two adjacent R10 groups taken together with the atoms to which they are attached form a fused, saturated, unsaturated or partially unsaturated 5 to 7 membered ring having 0, 1 or 2 heteroatoms selected from the group consisting of N, O, and S;

each R11 is, independently, H or an aliphatic group; and R12 is an aliphatic group; and D

or pharmaceutically acceptable salts, solvates or hydrates thereof, wherein:
R8 is a halo, nitro, alkylcarbonyl or trihaloalkyl;
p is 0 or an integer from 1 to 3; and each R13 is, independently, a halo, a substituted or unsubstituted heterocycle, or a substituted or unsubstituted heteroaryl.
22. A method of inhibiting homing of leukocytes to mucosal tissue in a subject in need of such treatment, comprising adiministering to the subject an effective amount of at least one compound represented by the following structural formula:

or pharmaceutically acceptable salts, solvates or hydrates thereof, wherein:
Y is C(O), S, S(O) or S(O)2;

X1, X2, and X3 are each, independently, N or CR, provided that at least one of X1, X2, or X3 is CR;
R, for each occurrence, and R1 are each, independently, H or a substituent;
R6 is H, an aliphatic group, an aryl group or an aliphatic carbonyl group;
ring A is substituted or unsubstituted; and Ar1 and Ar2 are each, independently, a substituted or unsubstituted aryl group or a substituted or unsubstituted heteroaryl group.
CA2485681A 2002-05-24 2003-05-21 Ccr9 inhibitors and methods of use thereof Expired - Lifetime CA2485681C (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CA2784937A CA2784937A1 (en) 2002-05-24 2003-05-21 Ccr9 inhibitors and methods of use thereof

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US38357302P 2002-05-24 2002-05-24
US60/383,573 2002-05-24
PCT/US2003/016090 WO2003099773A1 (en) 2002-05-24 2003-05-21 Ccr9 inhibitors and methods of use thereof

Related Child Applications (1)

Application Number Title Priority Date Filing Date
CA2784937A Division CA2784937A1 (en) 2002-05-24 2003-05-21 Ccr9 inhibitors and methods of use thereof

Publications (2)

Publication Number Publication Date
CA2485681A1 true CA2485681A1 (en) 2003-12-04
CA2485681C CA2485681C (en) 2012-10-16

Family

ID=29584585

Family Applications (2)

Application Number Title Priority Date Filing Date
CA2485681A Expired - Lifetime CA2485681C (en) 2002-05-24 2003-05-21 Ccr9 inhibitors and methods of use thereof
CA2784937A Abandoned CA2784937A1 (en) 2002-05-24 2003-05-21 Ccr9 inhibitors and methods of use thereof

Family Applications After (1)

Application Number Title Priority Date Filing Date
CA2784937A Abandoned CA2784937A1 (en) 2002-05-24 2003-05-21 Ccr9 inhibitors and methods of use thereof

Country Status (9)

Country Link
US (11) US7238717B2 (en)
EP (4) EP1507756B1 (en)
JP (7) JP4828822B2 (en)
AU (2) AU2003248549B2 (en)
CA (2) CA2485681C (en)
MX (1) MXPA04011465A (en)
NZ (2) NZ566263A (en)
WO (1) WO2003099773A1 (en)
ZA (1) ZA200409131B (en)

Families Citing this family (89)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2003095967A2 (en) * 2002-05-14 2003-11-20 Bayer Healthcare Ag Diagnostics and therapeutics for diseases associated with chemokine receptor 9(ccr9)
NZ566263A (en) * 2002-05-24 2009-09-25 Millennium Pharm Inc CCR9 inhibitors and methods of use thereof
US7227035B2 (en) * 2002-11-18 2007-06-05 Chemocentryx Bis-aryl sulfonamides
US7741519B2 (en) 2007-04-23 2010-06-22 Chemocentryx, Inc. Bis-aryl sulfonamides
AU2003298661B2 (en) * 2002-11-18 2007-05-10 Chemocentryx, Inc. Aryl sulfonamides
US7420055B2 (en) * 2002-11-18 2008-09-02 Chemocentryx, Inc. Aryl sulfonamides
EP2415760A3 (en) 2003-02-20 2012-02-22 Encysive Pharmaceuticals, Inc. CCR-9 antagonists
US7288538B2 (en) 2003-02-20 2007-10-30 Encysive Pharmaceuticals, Inc. Phenylenediamine urotensin-II receptor antagonists and CCR-9 antagonists
US7320989B2 (en) 2003-02-28 2008-01-22 Encysive Pharmaceuticals, Inc. Pyridine, pyrimidine, quinoline, quinazoline, and naphthalene urotensin-II receptor antagonists
EP1603884A4 (en) 2003-02-28 2008-05-28 Encysive Pharmaceuticals Inc Pyridine, pyrimidine, quinoline, quinazoline, and naphthalene urotensin-ii receptor antagonists.
DE102004027119A1 (en) 2003-06-06 2004-12-30 Schott Ag Production of a UV-absorbed glass used in the production of gas discharge lamps, fluorescent lamps, xenon lamps, LCD displays, computer monitors and telephone displays comprises melting a raw material and producing a melt
US7393873B2 (en) 2003-07-02 2008-07-01 Merck & Co., Inc. Arylsulfonamide derivatives
CA2549651A1 (en) * 2003-12-19 2005-07-07 Pfizer Inc. Benzenesulfonylamino-pyridin-2-yl derivatives and related compounds as inhibitors of 11-beta-hydroxysteroid dehydrogenase type 1 (11-beta-hsd-1) for the treatment of diabetes and obesity
US7479496B2 (en) 2004-02-19 2009-01-20 Bristol-Myers Squibb Company Substituted spiro azabicyclics as modulators of chemokine receptor activity
US7381738B2 (en) 2004-02-19 2008-06-03 Bristol-Myers Squibb Company Substituted bicycloalkylamine derivatives as modulators of chemokine receptor activity
US7288563B2 (en) 2004-02-19 2007-10-30 Bristol-Myers Squibb Company Substituted bicycloalkylamine derivatives as modulators of chemokine receptor activity
US7230022B2 (en) 2004-02-19 2007-06-12 Bristol-Myers Squibb Company Substituted fused bicyclic amines as modulators of chemokine receptor activity
US7932252B2 (en) 2004-05-12 2011-04-26 Chemocentryx, Inc. Aryl sulfonamides
DK1763517T3 (en) 2004-06-28 2011-06-06 Hoffmann La Roche Pyrimidine derivatives as 11beta-HSD1 inhibitors
CA2581865C (en) 2004-09-29 2010-04-20 F. Hoffmann-La Roche Ag Indazolone derivatives as 11b-hsd1 inhibitors
SE0402635D0 (en) * 2004-10-29 2004-10-29 Astrazeneca Ab Chemical compounds
WO2008109782A2 (en) * 2007-03-06 2008-09-12 Cedars-Sinai Medical Center Diagnosis of inflammatory bowel disease in children
AU2005314089B2 (en) * 2004-12-08 2011-03-03 Cedars-Sinai Medical Center Methods for diagnosis and treatment of Crohn's disease
EP2474532A1 (en) * 2005-01-14 2012-07-11 ChemoCentryx, Inc. Heteroaryl sulfonamides and CCR2
US7622583B2 (en) 2005-01-14 2009-11-24 Chemocentryx, Inc. Heteroaryl sulfonamides and CCR2
CA2610903A1 (en) * 2005-06-16 2006-12-21 Pfizer Inc. N-(pyridin-2-yl)-sulfonamide derivatives
FI20055498A0 (en) * 2005-09-16 2005-09-16 Biotie Therapies Corp Sulfonamides
GB0524786D0 (en) * 2005-12-05 2006-01-11 Glaxo Group Ltd Compounds
GB0526255D0 (en) * 2005-12-22 2006-02-01 Novartis Ag Organic compounds
GB0526252D0 (en) * 2005-12-22 2006-02-01 Novartis Ag Organic compounds
GB0526445D0 (en) * 2005-12-23 2006-02-08 Novartis Ag Organic compounds
US8519135B2 (en) * 2006-07-14 2013-08-27 Chemocentryx, Inc. Heteroaryl sulfonamides and CCR2/CCR9
EP2046762B1 (en) 2006-07-14 2011-02-16 ChemoCentryx, Inc. Triazolyl phenyl benzenesulfonamides
WO2008008374A2 (en) * 2006-07-14 2008-01-17 Chemocentryx, Inc. Ccr2 inhibitors and methods of use thereof
HUP0600810A3 (en) * 2006-10-27 2008-09-29 Richter Gedeon Nyrt New sulfonamide derivatives as bradykinin antagonists, process and intermediates for their preparation and pharmaceutical compositions containing them
TW200829578A (en) 2006-11-23 2008-07-16 Astrazeneca Ab Chemical compounds 537
JO2754B1 (en) 2006-12-21 2014-03-15 استرازينكا ايه بي Indazolyl amide derivatives for the treatment of glucocorticoid receptor mediated disorders
WO2008094992A2 (en) 2007-01-31 2008-08-07 Vertex Pharmaceuticals Incorporated 2-aminopyridine derivatives useful as kinase inhibitors
US20100021917A1 (en) * 2007-02-14 2010-01-28 Cedars-Sinai Medical Center Methods of using genes and genetic variants to predict or diagnose inflammatory bowel disease
US20100190162A1 (en) * 2007-02-26 2010-07-29 Cedars-Sinai Medical Center Methods of using single nucleotide polymorphisms in the tl1a gene to predict or diagnose inflammatory bowel disease
WO2010039931A2 (en) * 2008-10-01 2010-04-08 Cedars-Sinai Medical Center Methods of using il17rd and il23-il17 pathway genes to diagnose crohn's disease
WO2008116150A2 (en) 2007-03-21 2008-09-25 Cedars-Sinai Medical Center Ileal pouch-anal anastomosis (ipaa) factors in the treatment of inflammatory bowel disease
WO2008134569A2 (en) * 2007-04-26 2008-11-06 Cedars-Sinai Medical Center Diagnosis and treatment of inflammatory bowel disease in the puerto rican population
US20100144903A1 (en) * 2007-05-04 2010-06-10 Cedars-Sinai Medical Center Methods of diagnosis and treatment of crohn's disease
US7776877B2 (en) 2007-06-22 2010-08-17 Chemocentryx, Inc. N-(2-(hetaryl)aryl) arylsulfonamides and N-(2-(hetaryl) hetaryl arylsulfonamides
DK2175859T3 (en) * 2007-07-12 2012-06-18 Chemocentryx Inc CONDENSED HETEROARYL PYRIDYL AND PHENYLBENZENE SULPHONAMIDES AS CCR2 MODULATORS FOR TREATMENT OF INFLAMMATION
US20090028866A1 (en) * 2007-07-27 2009-01-29 John Wayne Cancer Institute USE OF CCR9, CCL25/TECK, AND NITEGRIN alpha4 IN DIAGNOSIS AND TREATMENT OF MELANOMA METASTASIS IN THE SMALL INTESTINE
UY31831A (en) 2008-05-20 2010-01-05 Astrazeneca Ab DERIVATIVES OF INDAZOLS REPLACED WITH PHENYLL OR PIRIDINYL
US8569337B2 (en) 2008-07-23 2013-10-29 Vertex Pharmaceuticals Incorporated Tri-cyclic pyrazolopyridine kinase inhibitors
AU2009274023A1 (en) 2008-07-23 2010-01-28 Vertex Pharmaceuticals Incorporated Tri-cyclic pyrazolopyridine kinase inhibitors
ES2402087T3 (en) 2008-07-23 2013-04-26 Vertex Pharmaceuticals Incorporated Pyrazolopyridine Kinase Inhibitors
WO2010017350A1 (en) 2008-08-06 2010-02-11 Vertex Pharmaceuticals Incorporated Aminopyridine kinase inhibitors
US20110189685A1 (en) * 2008-10-22 2011-08-04 Cedars-Sinai Medical Center Methods of using jak3 genetic variants to diagnose and predict crohn's disease
US20110229471A1 (en) * 2008-11-26 2011-09-22 Cedars-Sinai Medical Center Methods of determining responsiveness to anti-tnf alpha therapy in inflammatory bowel disease
US9580752B2 (en) 2008-12-24 2017-02-28 Cedars-Sinai Medical Center Methods of predicting medically refractive ulcerative colitis (MR-UC) requiring colectomy
AU2010245914A1 (en) 2009-05-06 2011-12-15 Vertex Pharmaceuticals Incorporated Pyrazolopyridines
AU2010276215A1 (en) * 2009-07-21 2012-02-16 Auckland Uniservices Limited Heteroaryl benzamides, compositions and methods of use
WO2011017120A1 (en) * 2009-07-27 2011-02-10 Cedars-Sinai Medical Center Use of ccr9, ccl25, batf and il17/il23 pathway variants to diagnose and treat inflammatory bowel disease
CA2787079A1 (en) 2010-01-27 2011-08-04 Vertex Pharmaceuticals Incorporated Pyrazolopyrazine kinase inhibitors
EP2582702A1 (en) 2010-01-27 2013-04-24 Vertex Pharmaceuticals Incorporated Pyrazolopyrimidine kinase inhibitors
CN102858769A (en) 2010-01-27 2013-01-02 沃泰克斯药物股份有限公司 Pyrazolopyridine kinase inhibitors
RU2654213C9 (en) 2010-12-16 2018-06-25 Аллерган, Инк. Novel 1,2-bis-sulphonamide derivatives as modulators of chemokine receptor
AU2011344148B2 (en) 2010-12-16 2017-04-27 Allergan, Inc. Phosphorous derivatives as chemokine receptor modulators
KR101303991B1 (en) * 2011-03-18 2013-09-04 성균관대학교산학협력단 Pharmaceutical composition for preventing or treating anti-inflammatory disease or infectious disease comprising m-3M3FBS as an effective component
CN107998388B (en) 2011-05-02 2023-07-14 千禧制药公司 Preparation of anti-alpha 4 beta 7 antibodies
UA116189C2 (en) 2011-05-02 2018-02-26 Мілленніум Фармасьютікалз, Інк. FORMULATION FOR ANTI-α4β7 ANTIBODY
BR112014001530B1 (en) * 2011-07-22 2022-05-31 Chemocentryx, Inc POLYMORPHIC FORMS OF 4-TERT-BUTYLN-[4-CHLORINE-2-(1-OXY-PYRIDINE-4-CARBONYL)- PHENYL]-BENZENE SULFONAMIDE, PHARMACEUTICAL COMPOSITION AND PRODUCTION METHOD
JP6122003B2 (en) * 2011-07-22 2017-04-26 ケモセントリックス， インコーポレイテッド Crystalline form of sodium salt of 4-tert-butyl-N- [4-chloro-2- (1-oxy-pyridine-4-carbonyl) -phenyl] -benzenesulfonamide
JP6166721B2 (en) 2011-07-22 2017-07-19 ケモセントリックス， インコーポレイテッド 4-tert-Butyl-N- [4-chloro-2- (1-oxy-pyridine-4-carbonyl) -phenyl] -benzenesulfonamide sodium salt polymorph
US8916601B2 (en) * 2012-02-29 2014-12-23 Chemocentryx, Inc. Aza-aryl 1H-pyrazol-1-YL benzene sulfonamides
DK2820010T3 (en) 2012-03-01 2018-08-06 Allergan Inc BENZOFURAN-2-SULPHONAMIDE DERIVATIVES AS CHEMOKIN RECEPTOR MODULATORS
WO2014008417A1 (en) 2012-07-04 2014-01-09 Concert Pharmaceuticals, Inc. Deuterated vercirnon
WO2014088113A1 (en) 2012-12-04 2014-06-12 Millennium Pharmaceuticals, Inc. Prophylactic or therapeutic method for sjogren's syndrome using specific ccr9 receptor inhibitors/antagonists
WO2014159657A1 (en) * 2013-03-12 2014-10-02 Allergan, Inc. Pyridinyl and pyrimidinyl sulfonamide derivatives as chemokine receptor modulators
AU2014241162A1 (en) 2013-03-27 2015-10-22 Cedars-Sinai Medical Center Mitigation and reversal of fibrosis and inflammation by inhibition of TL1A function and related signaling pathways
EP4105236A1 (en) 2013-07-19 2022-12-21 Cedars-Sinai Medical Center Anti-tl1a (tnfsf15) antibody for treatment of inflammatory bowel disease
US20170002011A1 (en) 2013-12-23 2017-01-05 Norgine B.V. Benzene sulfonamides as ccr9 inhibitors
US9969687B2 (en) 2013-12-23 2018-05-15 Norgine B.V. Compounds useful as CCR9 modulators
IL292655B2 (en) 2014-10-06 2024-03-01 Chemocentryx Inc Ccr9 chemokine receptor inhibitor for use in a method of treating or reducing the development of inflammatory bowel disease
EP3581585A1 (en) 2014-11-26 2019-12-18 Millennium Pharmaceuticals, Inc. Vedolizumab for the treatment of fistulizing crohn's disease
MA41636A (en) 2015-03-06 2018-01-09 Millennium Pharm Inc METHOD OF TREATMENT OF PRIMITIVE SCLEROSANT CHOLANGITIS
AU2017234010A1 (en) 2016-03-14 2018-09-27 Millennium Pharmaceuticals, Inc. Methods of treating or preventing graft versus host disease
EP3430052A2 (en) 2016-03-14 2019-01-23 Millennium Pharmaceuticals, Inc. Method of preventing graft versus host disease
CN109462996A (en) 2016-03-17 2019-03-12 西达-赛奈医疗中心 The method for diagnosing inflammatory bowel disease by RNASET2
RU2022102328A (en) 2016-11-23 2022-04-01 Хемоцентрикс, Инк. Method for the treatment of focal segmental glomerulosclerosis
CN110612120A (en) 2017-04-28 2019-12-24 千禧制药公司 Methods of treating pediatric disorders using antibodies specific for alpha 4 beta 7 integrin (vedolizumab)
RU2020113612A (en) 2017-10-11 2021-11-12 Хемоцентрикс, Инк. TREATMENT OF FOCAL-SEGMENTAL GLOMERULOSCLEROSIS WITH CCR2 ANTAGONISTS
US20210154292A1 (en) * 2019-11-21 2021-05-27 Chemocentryx, Inc. Compositions and Methods for Treating CCR9-Mediated Diseases using CCR9 Inhibitor and Anti-TNF-Alpha Blocking Antibodies
US10792360B1 (en) 2019-11-21 2020-10-06 Chemocentryx, Inc. Compositions and methods for treating inflammatory bowel disease using CCR9 inhibitor and anti-TNF-alpha blocking antibodies

Family Cites Families (118)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2997368A (en) * 1956-12-20 1961-08-22 Barent Mark Production of manganese hydroxide
GB884847A (en) * 1958-04-14 1961-12-20 Ciba Ltd Mercapto compounds
CH408940A (en) * 1959-12-10 1966-03-15 Hoffmann La Roche Process for the preparation of 1,4-benzodiazepine derivatives
DE1145626B (en) * 1959-12-10 1963-03-21 Hoffmann La Roche Process for the preparation of 3H-1, 4-Benzodiazepin-2 (1H) -one derivatives
US3442946A (en) * 1960-04-26 1969-05-06 Hoffmann La Roche 2-aminomercapto- and 2-aminoalkylcaptobenzophenone oximes
US3121103A (en) * 1961-10-20 1964-02-11 Hoffmann La Roche Aminobenzophenones
US3402171A (en) * 1960-12-02 1968-09-17 Hoffmann La Roche Process for preparing 5-aryl-3h-1, 4-benzodiazepin-2(1h)-ones
US3336295A (en) * 1960-12-02 1967-08-15 Hoffmann La Roche Hydroxy or alkoxy substituted 5-phenyl-3h-1, 4-benzodiazepin-2(1h)-ones
NL124621C (en) * 1962-11-13
US3534062A (en) * 1967-05-16 1970-10-13 Upjohn Co Dibenzothiadiazocines
US3551427A (en) 1969-05-09 1970-12-29 Sandoz Ag 4-thienyl-2-(1h)-quinazolones
CH561703A5 (en) 1970-12-11 1975-05-15 Hoffmann La Roche 7-Iodobenzodiazepin-2-ones - sedatives etc prepd by cyclising iodobenzophenones with glycine (esters)
GB1332697A (en) 1970-12-21 1973-10-03 Hoffmann La Roche Benzodiazepine derivatives
BE791902A (en) 1971-11-26 1973-05-24 Wander Ag Dr A NEW DERIVATIVES OF THIENO (3,2-C) (1) BENZAZEPINE, THEIR PREPARATION AND THEIR APPLICATION AS MEDICINAL PRODUCTS
US3846477A (en) * 1972-09-20 1974-11-05 Robins Co Inc A H 2-alkylamino benzophenones
CH585222A5 (en) 1973-02-14 1977-02-28 Wander Ag Dr A Prepn. of antipsychotic heterocyclic piperazine derivs. - by reaction of heterocyclic ketones with metal piperazine complexes
US4166452A (en) * 1976-05-03 1979-09-04 Generales Constantine D J Jr Apparatus for testing human responses to stimuli
US4256108A (en) * 1977-04-07 1981-03-17 Alza Corporation Microporous-semipermeable laminated osmotic system
FR2403330A1 (en) * 1977-06-16 1979-04-13 Fabre Sa Pierre NEW DERIVATIVES OF BENZOYL-2-CHLORO-4-GLYCINANILIDES SUBSTITUTES, THEIR METHOD OF PREPARATION AND THEIR APPLICATION AS MEDICINAL PRODUCTS
FR2449677B1 (en) 1979-02-26 1986-03-28 Fabre Sa Pierre NOVEL SUBSTITUTED BENZOYL-2 GLYCYLANILIDES DERIVATIVES, THEIR PREPARATION AND THEIR APPLICATION AS ANXIOLYTIC DRUGS
US4265874A (en) * 1980-04-25 1981-05-05 Alza Corporation Method of delivering drug with aid of effervescent activity generated in environment of use
US4312996A (en) * 1980-12-29 1982-01-26 Schering Corporation Benzodiazepine intermediates
DD251126A1 (en) 1984-12-21 1987-11-04 Univ Berlin Humboldt METHOD FOR PRODUCING NEW 2-ARYLSULFONAMIDO-BENZO AND -ACETOPHENONE AND THEIR OXIMES, PROCESS FOR THEIR PREPARATION AND THEIR USE IN MEDICAMENTS
US5010195A (en) * 1988-05-25 1991-04-23 The Dow Chemical Company Herbicidal alkoxy-1,2,4-triazolo(1,5-c)primidine-2-sulfonamides
US5021591A (en) * 1986-07-11 1991-06-04 The Dow Chemical Company Pyrazolo[1,5-a]pyrimidine-2-sulfide compounds
US4992091A (en) * 1986-07-11 1991-02-12 The Dow Chemical Company Substituted pyrazolo[1,5-a]pyrimidine-2-sulfonamides and compositions and methods of controlling undesired vegetation
US4997940A (en) * 1986-07-11 1991-03-05 The Dow Chemical Company Pyrazolo[1,5-a]pyrimidine-2-sulfonyl chloride and -2-sulfide compounds
JPH01156953A (en) * 1987-09-01 1989-06-20 Hokko Chem Ind Co Ltd Benzenesulfonanilide derivative and germicide for agriculture and horticulture
JPH0753725B2 (en) * 1987-10-08 1995-06-07 富山化学工業株式会社 4H-1-benzopyran-4-one derivative and its salt, their production method and anti-inflammatory agent containing them
DE3825041A1 (en) 1988-07-20 1990-02-15 Schering Ag Pyrido[3,2-e][1,2,4]triazolo[1,5-a]pyrimidine-2-sulphonamides, processes for their preparation, and their use as herbicides, plant growth regulators and fungicides
GB8820129D0 (en) * 1988-08-24 1988-09-28 Schering Agrochemicals Ltd Fungicides
GB8830182D0 (en) * 1988-12-23 1989-02-22 Shell Int Research Heterocyclic herbicides
US5217521A (en) * 1989-12-22 1993-06-08 Ciba-Geigy Corporation Triazolylsulfonamides
FR2665441B1 (en) * 1990-07-31 1992-12-04 Sanofi Sa N-SULFONYL INDOLINE DERIVATIVES, THEIR PREPARATION, THE PHARMACEUTICAL COMPOSITIONS CONTAINING SAME.
US5481005A (en) * 1990-07-31 1996-01-02 Sanofi N-sulfonylindoline derivatives, their preparation and the pharmaceutical compositions in which they are present
FR2679903B1 (en) 1991-08-02 1993-12-03 Elf Sanofi DERIVATIVES OF N-SULFONYL INDOLINE CARRYING AN AMIDIC FUNCTION, THEIR PREPARATION, THE PHARMACEUTICAL COMPOSITIONS CONTAINING SAME.
US5338755A (en) * 1990-07-31 1994-08-16 Elf Sanofi N-sulfonylindoline derivatives, their preparation and the pharmaceutical compositions in which they are present
DE4025818A1 (en) * 1990-08-16 1992-02-20 Bayer Ag PHENYL SULPHONAMIDE SUBSTITUTED PYRIDINALKEN AND -AMINOOXYALKANCARBONE ACID DERIVATIVES
US5185348A (en) * 1990-08-16 1993-02-09 Bayer Aktiengesellschaft Phenylsulphonamide substituted pyridinealkene- and -aminooxyalkanecarboxylic acid derivatives
JPH04248984A (en) * 1991-02-05 1992-09-04 Kuraray Co Ltd Superoxide dismutase derivative and production thereof
IE920175A1 (en) * 1991-02-11 1992-08-12 Zeneca Ltd Nitrogen heterocycles
IL101860A0 (en) * 1991-05-31 1992-12-30 Ici Plc Heterocyclic derivatives
RU2086544C1 (en) * 1991-06-13 1997-08-10 Хоффманн-Ля Рош АГ Benzenesulfonamide derivatives of pyrimidine or their salts, pharmaceutical composition for treatment of diseases associated with endothelin activity
JPH06145145A (en) 1991-12-27 1994-05-24 Ishihara Sangyo Kaisha Ltd Aminotrifluoromethylpyridine derivative or its salt, production thereof and phospholipase a2 inhibitor, antiinflammatory agent and antipancreatitic agent comprising the same
JPH06135934A (en) * 1991-12-27 1994-05-17 Ishihara Sangyo Kaisha Ltd Phospholipase a2 inhibitor, anti-inflammatory agent of anti-pancreatitic agent containing pyridine derivative or its salt
EP0556673B1 (en) 1992-02-15 1997-09-17 Hoechst Aktiengesellschaft Ortho-substituted benzoylguanidines, process for their preparation, their use as medicament or diagnostic agent, as well as medicaments containing them
JP3229668B2 (en) 1992-09-25 2001-11-19 株式会社リコー Telelighting device
TW287160B (en) * 1992-12-10 1996-10-01 Hoffmann La Roche
NZ250916A (en) 1993-02-27 1995-08-28 Nihon Nohyaku Co Ltd N-heteroaryl-n'-phenylureas, their use as acat inhibitors
US5514555A (en) 1993-03-12 1996-05-07 Center For Blood Research, Inc. Assays and therapeutic methods based on lymphocyte chemoattractants
TW394761B (en) * 1993-06-28 2000-06-21 Hoffmann La Roche Novel Sulfonylamino Pyrimidines
IL111959A (en) * 1993-12-17 2000-07-16 Tanabe Seiyaku Co N-(polysubstituted pyrimidin-4-yl) benzenesulfonamide derivatives their preparation and pharmaceutical compositions containing them
WO1995033462A1 (en) 1994-06-02 1995-12-14 Smithkline Beecham Corporation Anti-inflammatory compounds
JPH089412A (en) 1994-06-22 1996-01-12 Nec Eng Ltd Automatic chrominance signal correcting circuit
US5571775A (en) * 1994-07-11 1996-11-05 Dowelanco N-aryl[1,2,4]triazolo[1,5-a]pyridine-2-sulfonamide herbicides
FR2724654B1 (en) 1994-09-16 1997-12-12 Roussel Uclaf NEW GALLIC ACID DERIVATIVES, THEIR PREPARATION PROCESS, THE NEW INTERMEDIATES OBTAINED, THEIR APPLICATION AS MEDICAMENTS AND THE PHARMACEUTICAL COMPOSITIONS CONTAINING THEM
US5739333A (en) * 1995-05-16 1998-04-14 Tanabe Seiyaku Co., Ltd. Sulfonamide derivative and process for preparing the same
AU703892B2 (en) * 1995-09-06 1999-04-01 Kowa Co., Ltd. Pyrimidine derivatives
GB9602166D0 (en) 1996-02-02 1996-04-03 Zeneca Ltd Aminoheterocyclic derivatives
US5780488A (en) * 1996-04-03 1998-07-14 Merck & Co., Inc. Inhibitors of farnesyl-protein transferase
DE19629144A1 (en) * 1996-07-19 1998-01-22 Bayer Ag Substituted triazoloazine sulfonamides
WO1998011218A1 (en) 1996-09-10 1998-03-19 Theodor-Kocher Institute Cxcr3 chemokine receptor, antibodies, nucleic acids, and methods of use
AR015104A1 (en) * 1996-11-13 2001-04-18 Dowelanco SUBSTITUTED N-ARILSULFYLIMINE COMPOUNDS, USED AS CATALYSTS IN THE PREPARATION OF N-ARYLARILSULFONAMIDE COMPOUNDS; PROCESS TO PREPARE SUCH COMPOUNDS AND ITS USE TO CATALIZE SUCH PREPARATION.
TW523506B (en) * 1996-12-18 2003-03-11 Ono Pharmaceutical Co Sulfonamide or carbamide derivatives and drugs containing the same as active ingredients
SE9604786D0 (en) 1996-12-20 1996-12-20 Astra Pharma Inc New compounds
US6696475B2 (en) * 1997-04-22 2004-02-24 Neurosearch A/S Substituted phenyl derivatives, their preparation and use
CA2288330C (en) 1997-05-07 2014-02-11 University Of Pittsburgh Benzoyl amino acid derivatives useful as inhibitors of protein isoprenyl tranferases
HUP0003073A3 (en) * 1997-07-11 2002-10-28 Smithkline Beecham Plc Benzenesulfonamide derivatives, process for producing them and their use as medicines
US6297239B1 (en) * 1997-10-08 2001-10-02 Merck & Co., Inc. Inhibitors of prenyl-protein transferase
BR9814327A (en) 1997-12-23 2000-10-03 Warner Lambert Co Thiourea and benzamide compounds, compositions and processes for the treatment or prevention of inflammatory diseases and arteriosclerosis
US6200995B1 (en) * 1998-01-29 2001-03-13 Tularik Inc. PPAR-γ modulators
GB9803411D0 (en) 1998-02-18 1998-04-15 Smithkline Beecham Plc Novel compounds
JP4327915B2 (en) * 1998-03-30 2009-09-09 株式会社デ・ウエスタン・セラピテクス研究所 Sulfonamide derivatives
WO1999055324A1 (en) 1998-04-27 1999-11-04 Smithkline Beecham Corporation Ccr-3 receptor antagonists
WO1999055663A1 (en) 1998-04-29 1999-11-04 Vertex Pharmaceuticals Incorporated Inhibitors of impdh enzyme
US6136971A (en) * 1998-07-17 2000-10-24 Roche Colorado Corporation Preparation of sulfonamides
WO2000005214A2 (en) 1998-07-24 2000-02-03 Pfizer Inc. Isoquinolines as urokinase inhibitors
US6294192B1 (en) * 1999-02-26 2001-09-25 Lipocine, Inc. Triglyceride-free compositions and methods for improved delivery of hydrophobic therapeutic agents
US6329159B1 (en) * 1999-03-11 2001-12-11 Millennium Pharmaceuticals, Inc. Anti-GPR-9-6 antibodies and methods of identifying agents which modulate GPR-9-6 function
PL215901B1 (en) 1999-04-15 2014-02-28 Bristol Myers Squibb Co Cyclic protein tyrosine kinase inhibitors
MXPA01013199A (en) 1999-06-30 2003-08-20 Tularik Inc COMPOUNDS FOR THE MODULATION OF PPARgamma ACTIVITY.
US7041691B1 (en) * 1999-06-30 2006-05-09 Amgen Inc. Compounds for the modulation of PPARγ activity
AU6076000A (en) 1999-07-30 2001-02-19 Vertex Pharmaceuticals Incorporated Cyclic amine derivatives for the treatment of neurological diseases
ES2272319T3 (en) * 1999-08-27 2007-05-01 Chemocentryx, Inc. HETEROCICLICAL COMPOUNDS AND METHODS TO MODULATE THE CXCR3 FUNCTION.
WO2001017971A1 (en) 1999-09-06 2001-03-15 Takeda Chemical Industries, Ltd. Process for the preparation of 2,3-dihydroazepine derivatives
WO2001019788A2 (en) 1999-09-17 2001-03-22 Cor Therapeutics, Inc. BENZAMIDES AND RELATED INHIBITORS OF FACTOR Xa
RU2002110295A (en) 1999-09-17 2003-12-10 Милленниум Фармасьютикалс, Инк. (Us) Factor Xa Inhibitors
JP2001089412A (en) 1999-09-22 2001-04-03 Otsuka Pharmaceut Co Ltd Benzene derivative or its pharmaceutically acceptable salt
GB9926302D0 (en) 1999-11-05 2000-01-12 Smithkline Beecham Plc Novel compounds
EP1255750A1 (en) 2000-02-01 2002-11-13 Millenium Pharmaceuticals, Inc. INDOLE AND BENZIMIDAZOLE INHIBITORS OF FACTOR Xa
EP1255743A1 (en) * 2000-02-01 2002-11-13 Millenium Pharmaceuticals, Inc. 3,4-DIHYDRO-2H-BENZO[1,4]OXAZINE INHIBITORS OF FACTOR Xa
AU2001234689A1 (en) 2000-02-01 2001-08-14 Cor Therapeutics, Inc. Bivalent phenylene inhibitors of factor xa
KR100767000B1 (en) 2000-02-03 2007-10-15 에자이 알앤드디 매니지먼트 가부시키가이샤 Integrin expression inhibitors
GB2359078A (en) * 2000-02-11 2001-08-15 Astrazeneca Uk Ltd Pharmaceutically active pyrimidine derivatives
EP1214070A4 (en) 2000-02-18 2008-07-16 Arch Dev Corp Polyhydroxylated benzene-containing compounds
WO2001060369A1 (en) 2000-02-18 2001-08-23 Merck & Co., Inc. Inhibitors of prenyl-protein transferase
CO5300399A1 (en) * 2000-02-25 2003-07-31 Astrazeneca Ab HETEROCICLIOCS CONTAINING NITROGEN, PROCESS FOR PREPARATION AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM
JP3842976B2 (en) * 2000-03-17 2006-11-08 富士通株式会社 Distributed feedback semiconductor laser and manufacturing method thereof
WO2001082916A2 (en) * 2000-05-03 2001-11-08 Tularik Inc. Combination therapeutic compositions and methods of use
JP2002031867A (en) * 2000-05-08 2002-01-31 Fuji Photo Film Co Ltd Processing method for silver halide color photographic sensitive material
GB0011838D0 (en) * 2000-05-17 2000-07-05 Astrazeneca Ab Chemical compounds
WO2002000647A1 (en) * 2000-06-23 2002-01-03 Bristol-Myers Squibb Pharma Company Heteroaryl-phenyl substituted factor xa inhibitors
IL153461A0 (en) 2000-06-28 2003-07-06 Tularik Inc Quinolinyl and benzothiazolyl derivatives and pharmaceutical compositions containing the same
US20040029928A1 (en) 2000-08-31 2004-02-12 Terukage Hirata Novel propenohydroxamic acid derivatives
EP1578341A2 (en) 2000-10-11 2005-09-28 Tularik Inc. Modulation of ccr4 function
US20020147198A1 (en) 2001-01-12 2002-10-10 Guoqing Chen Substituted arylamine derivatives and methods of use
AR032230A1 (en) 2001-01-16 2003-10-29 Sumitomo Chem Takeda Agro Co SULFONAMIDE DERIVATIVE CONTAINING AN AGRICULTURAL AND HORTICALLY COMPOSITION
US6656971B2 (en) 2001-01-25 2003-12-02 Guilford Pharmaceuticals Inc. Trisubstituted carbocyclic cyclophilin binding compounds and their use
NZ566263A (en) * 2002-05-24 2009-09-25 Millennium Pharm Inc CCR9 inhibitors and methods of use thereof
US7420055B2 (en) 2002-11-18 2008-09-02 Chemocentryx, Inc. Aryl sulfonamides
AU2003298661B2 (en) 2002-11-18 2007-05-10 Chemocentryx, Inc. Aryl sulfonamides
EP1585511B1 (en) 2002-12-20 2013-01-23 Amgen Inc. Asthma and allergic inflammation modulators
US6993400B2 (en) * 2003-03-07 2006-01-31 Xerox Corporation System and method for real-time assignment of jobs to production cells
WO2004099127A1 (en) 2003-05-07 2004-11-18 Novo Nordisk A/S Novel compounds as kinase inhibitors
US7393873B2 (en) 2003-07-02 2008-07-01 Merck & Co., Inc. Arylsulfonamide derivatives
EP2474532A1 (en) 2005-01-14 2012-07-11 ChemoCentryx, Inc. Heteroaryl sulfonamides and CCR2
JP4364168B2 (en) 2005-07-11 2009-11-11 アルゼ株式会社 Game machine
WO2007014054A2 (en) 2005-07-22 2007-02-01 Glaxo Group Limted Benzenesulfonamide inhibitor of ccr2 chemokine receptor

Also Published As

Publication number Publication date
US20160068479A1 (en) 2016-03-10
JP5544283B2 (en) 2014-07-09
US20100093802A1 (en) 2010-04-15
US8569543B2 (en) 2013-10-29
WO2003099773A1 (en) 2003-12-04
US8030517B2 (en) 2011-10-04
US20070066823A1 (en) 2007-03-22
JP5548169B2 (en) 2014-07-16
US20040038976A1 (en) 2004-02-26
AU2010201073B2 (en) 2011-09-29
CA2784937A1 (en) 2003-12-04
CA2485681C (en) 2012-10-16
JP2011213740A (en) 2011-10-27
JP4818798B2 (en) 2011-11-16
US20100280074A1 (en) 2010-11-04
AU2010201073A1 (en) 2010-04-08
US20140107160A1 (en) 2014-04-17
AU2003248549B2 (en) 2010-04-08
JP2010047584A (en) 2010-03-04
US20060167251A1 (en) 2006-07-27
EP2402310A1 (en) 2012-01-04
US20100324093A1 (en) 2010-12-23
US7238717B2 (en) 2007-07-03
US20090054495A1 (en) 2009-02-26
JP2011105725A (en) 2011-06-02
JP5432221B2 (en) 2014-03-05
ZA200409131B (en) 2005-09-28
US7282502B2 (en) 2007-10-16
NZ566263A (en) 2009-09-25
EP1507756A4 (en) 2006-03-15
EP1507756A1 (en) 2005-02-23
NZ536504A (en) 2008-04-30
JP2014132018A (en) 2014-07-17
US20080103180A1 (en) 2008-05-01
MXPA04011465A (en) 2005-02-14
US9035096B2 (en) 2015-05-19
US7999109B2 (en) 2011-08-16
JP2005526857A (en) 2005-09-08
JP2006265259A (en) 2006-10-05
US20110313000A1 (en) 2011-12-22
JP4828822B2 (en) 2011-11-30
JP2011246486A (en) 2011-12-08
EP1507756B1 (en) 2015-07-22
AU2003248549A1 (en) 2003-12-12
US7820717B2 (en) 2010-10-26
EP2399903A1 (en) 2011-12-28
US7659272B2 (en) 2010-02-09
EP2402309A1 (en) 2012-01-04

Similar Documents

Publication Publication Date Title
CA2485681A1 (en) Ccr9 inhibitors and methods of use thereof
AU2007205711B2 (en) Aryl sulfonamides
KR870007137A (en) Substituted pyridine sulfonamide compounds, herbicidal compositions containing them and methods for producing these compounds.
CA2579002C (en) Pyridyl inhibitors of hedgehog signalling
WO2005112925A1 (en) Aryl sulfonamides
KR102534262B1 (en) Heterocyclic derivatives and use thereof
JP6619333B2 (en) Heterocyclic derivatives and uses thereof
NO20081464L (en) 1-heterocycle sulfonyl, 2-aminomethyl, 5- (hetero-) aryl subsidized 1-H-pyrrole derivatives as acid secretion inhibitors
RU2017103753A (en) A pyridone derivative having a tetrahydropyranyl methyl group
CA2574875A1 (en) Aryl-pyridine derivatives as 11-beta hsd1 inhibitors
CA2396824A1 (en) Heteroaromatic carboxamide derivatives and their use as inhibitors of the enzyme ikk-2
JP2009516685A5 (en)
KR101846475B1 (en) COMPOUNDS AS TNIK, IKKε AND TBK1 INHIBITORS AND PHARMACEUTICAL COMPOSITION COMPRISING SAME
AU5671799A (en) Heteroaryl amidines, methylamidines and guanidines as protease inhibitors
WO2011161201A1 (en) Bisarylsulfonamides useful as kinase inhibitors in the treatment of inflammation and cancer
KR940019686A (en) New pyridinium derivatives
PE20081683A1 (en) NEW SULFONAMIDE DERIVATIVES
JP2017524017A5 (en)
AU2011344125B2 (en) Novel 1,2- bis-sulfonamide derivatives as chemokine receptor modulators
AU2017261491A1 (en) Pyridyl Inhibitors of Hedgehog Signalling

Legal Events

Date Code Title Description
EEER Examination request
MKEX Expiry

Effective date: 20230523